Condition: Primary Hyperoxaluria Type 1 (PH1) · Sponsor: Arbor Biotechnologies
The goal of the redePHine study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ABO-101 in participants with primary hyperoxaluria type 1 (PH1). The trial will consist of 2 Study Periods. During the first Study Period, there will be 2 parts. In Part A, adult participants will be treated with a single ascending dose to identify a recommended dose. In Part B, pediatric participants will be treated with the recommended dose. Following the first Study Period, participants will start Study Period 2, a long-term monitoring program to comply with local and national requirements.
This description comes directly from the study's public registry record.
Daniel Ory, MD · 617-500-8941 · arbortrials@arbor.bio
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Nucleus Network | Saint Paul, Minnesota, United States | Withdrawn |
| Hospices Civils de Lyon- Hôpital Femmes Mères Enfants | Lyon, France | Not Yet Recruiting |
| Kindernierenzentrum Bonn | Bonn, Germany | Not Yet Recruiting |
| Heidi Chaker | Sfax, Tunisia | Recruiting |
| Queen Elizabeth Hospital Birmingham | Birmingham, United Kingdom | Recruiting |
| Royal Free Hospital | London, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06839235